Pfizer reportedly considers buying Protalix
Pfizer visited facilities of Israel's Protalix Biotherapeutics as part of talks to team up with or acquire the company, newspaper TheMarker reported. Protalix was not available for comment. Protalix recently reported a successful trial of its Gaucher disease drug Uplyso, which could compete with Genzyme's Cerezyme if approved.
Forbes | 11/02
This story published in BIO SmartBrief on 11/03/2009
More from SmartBrief:
FDA grants orphan-drug status to Protalix's Gaucher drug
Wednesday, September 9, 2009
FDA OKs treatment protocol for Protalix's Gaucher drug
Tuesday, August 18, 2009
FDA fast-tracks review of Gaucher's drug by Protalix
Wednesday, August 26, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|